BRPI0513200A - uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas - Google Patents
uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicasInfo
- Publication number
- BRPI0513200A BRPI0513200A BRPI0513200-2A BRPI0513200A BRPI0513200A BR PI0513200 A BRPI0513200 A BR PI0513200A BR PI0513200 A BRPI0513200 A BR PI0513200A BR PI0513200 A BRPI0513200 A BR PI0513200A
- Authority
- BR
- Brazil
- Prior art keywords
- igf
- antibody
- preparation
- malignancies
- combined treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
USO DE UM ANTICORPO ANTI-IGF-1R NA PREPARAçãO DE UM MEDICAMENTO PARA TRATAMENTO COMBINADO PARA MALIGNIDADES NãO-HEMATOLóGICAS. A presente invenção refere-se a um método terapêutico de malignidades não-hematológicas, compreendendo administrar anticorpos anti-IGF-lR, particularmente anticorpos anti-IGF-lR humanos, a um paciente, em conjunto com a administração de pelo menos um outro agente terapêutico. A invenção refere-se ainda a usos e composições farmacêuticas que compreendem estes anticorpos, e métodos para usar tais composições para esse tratamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58872104P | 2004-07-16 | 2004-07-16 | |
PCT/IB2005/002096 WO2006008639A1 (en) | 2004-07-16 | 2005-07-04 | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0513200A true BRPI0513200A (pt) | 2008-04-29 |
Family
ID=35058695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0513200-2A BRPI0513200A (pt) | 2004-07-16 | 2005-07-04 | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas |
Country Status (17)
Country | Link |
---|---|
US (2) | US7618626B2 (pt) |
EP (4) | EP2322217A3 (pt) |
JP (1) | JP2008506681A (pt) |
KR (2) | KR20080019733A (pt) |
CN (1) | CN101014365B (pt) |
AR (1) | AR049985A1 (pt) |
AU (2) | AU2005264063B2 (pt) |
BR (1) | BRPI0513200A (pt) |
CA (1) | CA2573821A1 (pt) |
HK (1) | HK1105151A1 (pt) |
IL (4) | IL180422A0 (pt) |
MX (1) | MX2007000610A (pt) |
NO (1) | NO20070702L (pt) |
NZ (1) | NZ552091A (pt) |
RU (1) | RU2342159C2 (pt) |
TW (2) | TWI309167B (pt) |
WO (1) | WO2006008639A1 (pt) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101086533B1 (ko) * | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
US7310537B2 (en) * | 2003-04-25 | 2007-12-18 | Nokia Corporation | Communication on multiple beams between stations |
EP1622942B1 (en) | 2003-05-01 | 2014-11-19 | ImClone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
WO2005047512A2 (en) | 2003-11-12 | 2005-05-26 | Shering Corporation | Plasmid system for multigene expression |
PE20050928A1 (es) * | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
WO2006060419A2 (en) * | 2004-12-03 | 2006-06-08 | Schering Corporation | Biomarkers for pre-selection of patients for anti-igf1r therapy |
CN101222926B (zh) * | 2005-04-15 | 2013-07-17 | 默沙东公司 | 用于治疗或预防癌症的方法和组合物 |
NZ564098A (en) * | 2005-06-15 | 2010-04-30 | Schering Corp | Anti-IGF1R antibody formulations |
SI2100614T1 (sl) | 2005-06-17 | 2014-03-31 | Imclone Llc | PROTITELO PROTI PDGFR-alfa ZA UPORABO PRI ZDRAVLJENJU TUMORJEV |
EP2372363A1 (en) | 2005-09-20 | 2011-10-05 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
WO2007061737A2 (en) | 2005-11-17 | 2007-05-31 | Osi Pharmaceuticals, Inc. | FUSED BICYCLIC mTOR INHIBITORS |
EA017265B1 (ru) | 2006-02-03 | 2012-11-30 | Имклоун Элэлси | Применение антитела imc-a12, которое является ингибитором igf-ir, для лечения рака предстательной железы |
US7846724B2 (en) | 2006-04-11 | 2010-12-07 | Hoffmann-La Roche Inc. | Method for selecting CHO cell for production of glycosylated antibodies |
EP1854465A1 (en) | 2006-05-12 | 2007-11-14 | Alexander Tobias Teichmann | Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers |
EP2338488A1 (en) * | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
NZ573187A (en) * | 2006-06-02 | 2011-11-25 | Pfizer Prod Inc | Circulating tumor cell assay for predicting efficacy of 1gf-1r antagonist therapy |
US20090068110A1 (en) * | 2006-12-22 | 2009-03-12 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
AU2012203443B2 (en) * | 2007-03-02 | 2014-03-06 | Amgen Inc. | Methods and compositions for treating tumor diseases |
JP2010520204A (ja) * | 2007-03-02 | 2010-06-10 | アムジェン インコーポレイテッド | 腫瘍疾患を治療するための方法および組成物 |
WO2008144720A2 (en) * | 2007-05-21 | 2008-11-27 | University Of Washington | Inhibitors of igf-1r signaling for the treatment of respiratory disorders |
PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
EP2178563A2 (en) * | 2007-07-06 | 2010-04-28 | OSI Pharmaceuticals, Inc. | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2 |
JP2010532758A (ja) * | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 組み合わせ抗癌療法 |
EP2208066A2 (en) * | 2007-10-03 | 2010-07-21 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2201378A2 (en) * | 2007-10-03 | 2010-06-30 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
ES2388017T3 (es) | 2007-12-21 | 2012-10-05 | Roche Glycart Ag | Ensayo de estabilidad de anticuerpos |
JP2011118449A (ja) | 2008-03-26 | 2011-06-16 | Japan Breast Cancer Research Group | 投与方法提案装置 |
BRPI0916138A2 (pt) | 2008-11-22 | 2015-11-17 | Genentech Inc | "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito" |
KR101827332B1 (ko) | 2008-12-12 | 2018-02-09 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-igf 항체 |
JP2012519170A (ja) * | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法 |
EP2236139A1 (en) | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
US20120121589A1 (en) * | 2009-07-13 | 2012-05-17 | Wayne State University | Modified egfr ectodomain |
KR102223417B1 (ko) | 2009-10-26 | 2021-03-05 | 에프. 호프만-라 로슈 아게 | 글리코실화된 면역글로불린의 제조 방법 |
EP2509421B1 (en) | 2009-12-10 | 2020-02-05 | Cedars-Sinai Medical Center | Drug delivery of temozolomide for systemic based treatment of cancer |
WO2011101328A2 (en) | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
AU2011223655A1 (en) * | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
US9623041B2 (en) | 2010-12-30 | 2017-04-18 | Cedars-Sinai Medical Center | Polymalic acid-based nanobiopolymer compositions |
JP2014504591A (ja) * | 2010-12-30 | 2014-02-24 | セダーズ−シナイ メディカル センター | ポリリンゴ酸ベースのナノバイオポリマー組成物およびがんを治療するための方法 |
JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
US20130122005A1 (en) * | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
EP2631653A1 (en) | 2012-02-24 | 2013-08-28 | Charité - Universitätsmedizin Berlin | Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family |
EP2914629A1 (en) | 2012-11-05 | 2015-09-09 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
US20140255413A1 (en) * | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
CN103319598B (zh) * | 2013-05-13 | 2014-10-22 | 杭州德同生物技术有限公司 | 抗胰岛素样生长因子-1受体抗体及其编码基因和应用 |
AR103896A1 (es) | 2015-03-09 | 2017-06-14 | Agensys Inc | Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3 |
US9923862B2 (en) * | 2015-06-23 | 2018-03-20 | International Business Machines Corporation | Communication message consolidation with content difference formatting |
WO2021025554A1 (en) | 2019-08-02 | 2021-02-11 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination comprising an activator of the glucocorticoid receptor and an inhibitor of ifg-1 signaling for carcinoma treatment |
CN113512116B (zh) | 2020-04-10 | 2022-09-20 | 苏州普乐康医药科技有限公司 | 一种抗igf-1r抗体及其应用 |
CN116583273A (zh) * | 2020-10-14 | 2023-08-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
US20220267450A1 (en) | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
WO2024047130A1 (en) | 2022-08-31 | 2024-03-07 | Relaxera Pharmazeutische Gesellschaft mbH & Co. KG | Immunosuppressive medicament and method of treatment |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US577085A (en) * | 1897-02-16 | Bicycle-saddle carriage | ||
US3561444A (en) | 1968-05-22 | 1971-02-09 | Bio Logics Inc | Ultrasonic drug nebulizer |
US3703173A (en) | 1970-12-31 | 1972-11-21 | Ted A Dixon | Nebulizer and tent assembly |
US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) * | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US4624251A (en) | 1984-09-13 | 1986-11-25 | Riker Laboratories, Inc. | Apparatus for administering a nebulized substance |
US4635627A (en) | 1984-09-13 | 1987-01-13 | Riker Laboratories, Inc. | Apparatus and method |
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4968516A (en) * | 1989-07-24 | 1990-11-06 | Thompson Neal W | Method and apparatus for cooking foodstuffs using auxiliary steam |
CA2065299C (en) | 1989-08-09 | 2001-07-24 | Buck A. Rhodes | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5151510A (en) * | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992003917A1 (en) * | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
AU2515992A (en) * | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
JP3540315B2 (ja) | 1991-09-23 | 2004-07-07 | メディカル リサーチ カウンシル | キメラ抗体の製造−組合せアプローチ |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
WO1993016185A2 (en) * | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
ATE208374T1 (de) * | 1992-02-18 | 2001-11-15 | Otsuka Kagaku Kk | Beta-laktam und cepham verbindungen und ihre herstellung |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
ES2146648T3 (es) | 1993-03-09 | 2000-08-16 | Genzyme Corp | Procedimiento de aislamiento de proteinas de la leche. |
US5625825A (en) * | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5643763A (en) * | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
ATE198326T1 (de) | 1995-04-20 | 2001-01-15 | Pfizer | Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf |
WO1996033266A1 (en) | 1995-04-21 | 1996-10-24 | Cell Genesys, Inc. | Generation of large genomic dna deletions |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
EP0861267A4 (en) * | 1995-11-14 | 2000-02-02 | Univ Jefferson | INDUCTION AND RESISTANCE TO TUMOR GROWTH BY MEANS OF SOLUBLE IGF-1 |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
EP0780386B1 (en) | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) * | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
IL118626A0 (en) * | 1996-06-11 | 1996-10-16 | Xtl Biopharmaceuticals Limited | Anti HBV antibody |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
PL331154A1 (en) | 1996-07-13 | 1999-06-21 | Glaxo Group Ltd | Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase |
JP4386967B2 (ja) | 1996-07-13 | 2009-12-16 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物 |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク. | 治療薬としてのcd147結合分子 |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
PT1004578E (pt) | 1998-11-05 | 2004-06-30 | Pfizer Prod Inc | Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico |
EE05483B1 (et) | 1998-12-23 | 2011-10-17 | Pfizer, Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
HUP0203153A3 (en) * | 1999-11-10 | 2005-01-28 | Warner Lambert Co | Combination chemotherapy |
US6593308B2 (en) * | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
SK16022002A3 (sk) * | 2000-05-15 | 2003-04-01 | Pharmacia Italia S. P. A. | Inhibítory aromatázy a monoklonálne anti-HER2 protilátky ako antitumorové činidlá |
US20030165502A1 (en) * | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
CZ20023951A3 (cs) | 2000-06-22 | 2004-01-14 | Pfizer Products Inc. | Substituované bicyklické deriváty pro léčení abnormálního buničného růstu |
PL217921B1 (pl) * | 2001-01-05 | 2014-09-30 | Amgen Fremont Inc | Przeciwciało przeciw receptorowi insulinopodobnego czynnika wzrostu I, zawierająca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana cząsteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierzę transgeniczne |
KR101086533B1 (ko) * | 2002-05-24 | 2011-11-23 | 쉐링 코포레이션 | 중화 사람 항-igfr 항체, 이를 제조하는 방법 및 이를 포함하는 조성물 |
US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
JP4305808B2 (ja) * | 2002-07-03 | 2009-07-29 | 太陽誘電株式会社 | 積層コンデンサ |
MXPA05009837A (es) | 2003-03-14 | 2005-12-05 | Pharmacia Corp | Anticuerpos para el receptor del factor de crecimiento tipo insulina-i, para el tratamiento de canceres. |
EP1613658B1 (en) | 2003-04-02 | 2012-03-14 | F. Hoffmann-La Roche AG | Antibodies against insulin-like growth factor i receptor and uses thereof |
EP1622942B1 (en) * | 2003-05-01 | 2014-11-19 | ImClone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
AU2004265152A1 (en) | 2003-08-13 | 2005-02-24 | Pfizer Products Inc. | Modified human IGF-1R antibodies |
-
2005
- 2005-07-04 EP EP10180530A patent/EP2322217A3/en not_active Withdrawn
- 2005-07-04 KR KR1020087003932A patent/KR20080019733A/ko not_active Application Discontinuation
- 2005-07-04 CA CA002573821A patent/CA2573821A1/en not_active Abandoned
- 2005-07-04 AU AU2005264063A patent/AU2005264063B2/en not_active Ceased
- 2005-07-04 EP EP10180525A patent/EP2322215A3/en not_active Withdrawn
- 2005-07-04 RU RU2007101387/14A patent/RU2342159C2/ru not_active IP Right Cessation
- 2005-07-04 NZ NZ552091A patent/NZ552091A/en not_active IP Right Cessation
- 2005-07-04 EP EP05757374A patent/EP1802341A1/en not_active Withdrawn
- 2005-07-04 KR KR1020077001027A patent/KR20070036130A/ko not_active Application Discontinuation
- 2005-07-04 WO PCT/IB2005/002096 patent/WO2006008639A1/en active Application Filing
- 2005-07-04 EP EP10180540A patent/EP2335727A3/en not_active Withdrawn
- 2005-07-04 MX MX2007000610A patent/MX2007000610A/es not_active Application Discontinuation
- 2005-07-04 JP JP2007520919A patent/JP2008506681A/ja active Pending
- 2005-07-04 BR BRPI0513200-2A patent/BRPI0513200A/pt not_active IP Right Cessation
- 2005-07-04 CN CN2005800240273A patent/CN101014365B/zh not_active Expired - Fee Related
- 2005-07-14 AR ARP050102924A patent/AR049985A1/es unknown
- 2005-07-15 TW TW094124112A patent/TWI309167B/zh not_active IP Right Cessation
- 2005-07-15 US US11/182,343 patent/US7618626B2/en not_active Expired - Fee Related
- 2005-07-15 TW TW096137976A patent/TW200812621A/zh unknown
-
2006
- 2006-12-28 IL IL180422A patent/IL180422A0/en unknown
-
2007
- 2007-02-07 NO NO20070702A patent/NO20070702L/no not_active Application Discontinuation
- 2007-09-21 HK HK07110312.3A patent/HK1105151A1/xx not_active IP Right Cessation
-
2009
- 2009-08-17 AU AU2009210360A patent/AU2009210360B2/en not_active Ceased
- 2009-09-25 US US12/567,040 patent/US20110014207A1/en not_active Abandoned
-
2010
- 2010-12-30 IL IL210399A patent/IL210399A0/en unknown
- 2010-12-30 IL IL210401A patent/IL210401A0/en unknown
- 2010-12-30 IL IL210400A patent/IL210400A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
BRPI0418029B8 (pt) | formulação farmacêutica líquida, estável, adequada para administração parentérica que compreende um anticorpo agonista de cd40 | |
TR200001891T2 (tr) | ASPB28- İnsan ensülini ve kullanımı. | |
HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
BRPI0407485A (pt) | utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina | |
BR0108730A (pt) | Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados | |
BRPI0518460A2 (pt) | mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia' | |
PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
HUP0102489A2 (hu) | Biokémiai anyagok alkalmazása emberi test szerveiben található simaizomsejtek összehúzódása okozta egészségi állapotok megelőzésére és kezelésére alkalmas készítményekben | |
BRPI0411451A (pt) | formas de dosagens orais de memantina | |
AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
BR112013010829A2 (pt) | composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma | |
BRPI0607172A2 (pt) | método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos | |
BRPI0520797A2 (pt) | forma de dosagem farmacêutica, comprimido farmacêutico, método para quebrar um comprimido farmacêutico, método de administração de uma dose parcial de uma droga contida em um comprimido farmacêutico, método para reduzir o risco ou impedir a confusão do paciente em um tratamento, comprimido farmacêutico prensado, método para quebrar um comprimido farmacêutico prensado e método para a criação de uma quantidade precisa de uma droga | |
BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
EA201592040A1 (ru) | Иммуногенная композиция для применения в терапии | |
AR048806A1 (es) | Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio | |
BR0116653A (pt) | Medicamento contendo uma poliamina como substância ativa | |
BR0107881A (pt) | Uso de fsh tratamento de infertilidade | |
ATE301452T1 (de) | Verfahren zur herstellung einer flüssigen dosierungseinheit und kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2207 DE 24/04/2013. |